Display options
Cite
Elisabetsky E, Costa-Campos L. The alkaloid alstonine: a review of its pharmacological properties. Evid Based Complement Alternat Med. 2006;3(1):39-48doi: 10.1093/ecam/nek011.
Elisabetsky, E., & Costa-Campos, L. (2006). The alkaloid alstonine: a review of its pharmacological properties. Evidence-based complementary and alternative medicine : eCAM, 3(1), 39-48. https://doi.org/10.1093/ecam/nek011
Elisabetsky, E, and Costa-Campos, L. "The alkaloid alstonine: a review of its pharmacological properties." Evidence-based complementary and alternative medicine : eCAM vol. 3,1 (2006): 39-48. doi: https://doi.org/10.1093/ecam/nek011
Elisabetsky E, Costa-Campos L. The alkaloid alstonine: a review of its pharmacological properties. Evid Based Complement Alternat Med. 2006 Mar;3(1):39-48. doi: 10.1093/ecam/nek011. Epub 2006 Jan 16. PMID: 16550222; PMCID: PMC1375234.
Copy Download .nbib Format: NLM
Share it on

Evid Based Complement Alternat Med. 2006 Mar;3(1):39-48. doi: 10.1093/ecam/nek011. Epub 2006 Jan 16.

The alkaloid alstonine: a review of its pharmacological properties.

Evidence-based complementary and alternative medicine : eCAM

E Elisabetsky, L Costa-Campos

Affiliations

  1. Laboratório de Etnofarmacologia, ICBS, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. [email protected]

PMID: 16550222 PMCID: PMC1375234 DOI: 10.1093/ecam/nek011

Abstract

Indole compounds, related to the metabolism of tryptophan, constitute an extensive family, and are found in bacteria, plants and animals. Indolic compounds possess significant and complex physiological roles, and especially indole alkaloids have historically constituted a class of major importance in the development of new plant derived drugs. The indole alkaloid alstonine has been identified as the major component of a plant-based remedy, used in Nigeria to treat mental illnesses by traditional psychiatrists. Although it is certainly difficult to compare the very concept of mental disorders in different cultures, the traditional use of alstonine is remarkably compatible with its profile in experimental animals. Even though alstonine in mice models shows a psychopharmacological profile closer to the newer atypical antipsychotic agents, it also shows important differences and what seems to be an exclusive mechanism of action, not entirely clarified at this point. Considering the seemingly unique mode of action of alstonine and that its traditional use can be viewed as indicative of bioavailability and safety, this review focuses on the effects of alstonine in the central nervous system, particularly on its unique profile as an antipsychotic agent. We suggest that a thorough understanding of traditional medical concepts of health and disease in general and traditional medical practices in particular, can lead to true innovation in paradigms of drug action and development. Overall, the study of this unique indole alkaloid may be considered as another example of the richness of medicinal plants and traditional medical systems in the discovery of new prototypic drugs.

References

  1. Epilepsia. 1995;36 Suppl 1:S30-5 - PubMed
  2. Pharmacol Ther. 1993 Jan;57(1):1-78 - PubMed
  3. Pharmacol Biochem Behav. 1998 May;60(1):133-41 - PubMed
  4. Prog Neurobiol. 1998 Apr;54(5):581-618 - PubMed
  5. J Psychiatry Neurosci. 2004 Jul;29(4):287-93 - PubMed
  6. Eur J Pharmacol. 1989 Oct 4;169(1):1-10 - PubMed
  7. Science. 2002 Jul 19;297(5580):400-3 - PubMed
  8. Pharmacol Biochem Behav. 1998 Aug;60(4):873-8 - PubMed
  9. Can J Physiol Pharmacol. 1976 Aug;54(4):516-9 - PubMed
  10. J Ethnopharmacol. 1992 Apr;36(2):133-5 - PubMed
  11. J Ethnopharmacol. 2004 Aug;93(2-3):307-10 - PubMed
  12. Psychopharmacology (Berl). 2003 Sep;169(3-4):215-33 - PubMed
  13. Pharmacol Biochem Behav. 2002 Apr;71(4):555-68 - PubMed
  14. Ir J Med Sci. 2004 Jul-Sep;173(3):155-9 - PubMed
  15. Neurology. 1999;53(5 Suppl 2):S68-75 - PubMed
  16. Pharmacopsychiatry. 2003 Jan;36(1):7-11 - PubMed
  17. Pharmacol Biochem Behav. 2004 Mar;77(3):481-9 - PubMed
  18. Trends Neurosci. 1989 Jan;12(1):6-10 - PubMed
  19. Arch Gen Psychiatry. 1992 Mar;49(3):195-205 - PubMed
  20. Anal Bioanal Chem. 2003 May;376(1):33-7 - PubMed
  21. Behav Neurosci. 2002 Jun;116(3):464-71 - PubMed
  22. Eur J Pharmacol. 1997 Sep 24;335(2-3):117-25 - PubMed
  23. Br J Pharmacol. 1984 Oct;83(2):505-10 - PubMed
  24. Neuropsychobiology. 1986;16(2-3):93-6 - PubMed
  25. Oncology. 1986;43(3):198-203 - PubMed
  26. Exp Neurol. 1969 Nov;25(3):295-330 - PubMed
  27. Eur J Pharmacol. 1993 Jun 11;237(1):1-7 - PubMed
  28. Epilepsia. 2002;43 Suppl 2:8-13 - PubMed
  29. Altern Med Rev. 2001 Dec;6(6):567-79 - PubMed
  30. Schizophr Res. 2001 Sep 1;51(2-3):171-80 - PubMed
  31. Ir J Med Sci. 1978 Aug;147 Suppl 1:38-42 - PubMed
  32. Neuropharmacology. 1987 Jul;26(7B):877-86 - PubMed
  33. Annu Rev Neurosci. 1993;16:207-22 - PubMed
  34. Epilepsia. 2002;43 Suppl 2:19-24 - PubMed
  35. Prog Neurobiol. 2003 Jun;70(2):83-244 - PubMed
  36. Eur J Pharmacol. 2001 May 18;420(1):33-43 - PubMed
  37. Neurology. 1994 Nov;44(11 Suppl 8):S14-23 - PubMed
  38. An Acad Bras Cienc. 1999;71(2):189-201 - PubMed
  39. Evid Based Complement Alternat Med. 2005 Sep;2(3):285-99 - PubMed
  40. Biochem Cell Biol. 1990 Dec;68(12):1344-51 - PubMed
  41. Eur J Pharmacol. 1998 May 29;350(1):21-9 - PubMed
  42. Phytother Res. 2001 May;15(3):183-205 - PubMed
  43. Br J Pharmacol. 1995 Dec;116(7):2989-99 - PubMed
  44. Expert Opin Ther Targets. 2001 Dec;5(6):685-695 - PubMed
  45. Pharmacol Biochem Behav. 1999 Apr;62(4):727-34 - PubMed
  46. Behav Brain Res. 2001 Sep 28;124(1):87-95 - PubMed
  47. Neuropsychopharmacology. 1998 Mar;18(3):197-209 - PubMed
  48. Brain Res Brain Res Rev. 2000 Mar;31(2-3):288-94 - PubMed
  49. Evid Based Complement Alternat Med. 2005 Jun;2(2):201-207 - PubMed
  50. Prog Brain Res. 1994;102:227-43 - PubMed
  51. J Ethnopharmacol. 1984 Jun;11(1):99-117 - PubMed
  52. Br J Psychiatry Suppl. 1999;(38):5-11 - PubMed
  53. Life Sci. 2003 Apr 18;72(22):2429-49 - PubMed
  54. Mol Psychiatry. 2005 Jan;10(1):79-104 - PubMed
  55. J Ethnopharmacol. 1990 Apr;29(1):51-7 - PubMed
  56. Psychopharmacology (Berl). 1999 Jan;141(3):267-78 - PubMed
  57. J Pharmacol Exp Ther. 2000 Oct;295(1):226-32 - PubMed
  58. Behav Brain Res. 2003 Mar 18;140(1-2):203-14 - PubMed
  59. J Neurosci. 2001 Jan 15;21(2):750-7 - PubMed
  60. Eur J Pharmacol. 1984 Oct 30;106(1):203-5 - PubMed
  61. Soc Psychiatry Psychiatr Epidemiol. 2001 May;36(5):235-43 - PubMed
  62. J Ethnopharmacol. 1991 Jul;33(3):263-7 - PubMed
  63. Neuropsychobiology. 2003;48(1):27-30 - PubMed
  64. Afr J Med Med Sci. 1994 Mar;23(1):85-90 - PubMed
  65. Pharmacopsychiatry. 2000 Sep;33 Suppl 1:34-42 - PubMed
  66. Synapse. 1999 Dec 15;34(4):266-76 - PubMed
  67. Pharmacol Ther. 1994;64(2):291-370 - PubMed
  68. Psychopharmacologia. 1975 Oct 14;44(1):53-9 - PubMed
  69. Exp Cell Biol. 1982;50(2):79-87 - PubMed
  70. Eur J Pharmacol. 1995 Jul 4;280(2):R9-11 - PubMed
  71. J Ethnopharmacol. 1989 May;25(3):263-8 - PubMed

Publication Types